Viral load rebound, symptom rebound common with VV116, nirmatrelvir-ritonavir in mild-to-moderate COVID-19 For patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound can occur after a standard five-day course of treatment with VV116 or nirmatrelvir-ritonavir, according to a study published online March 13 in JAMA Network Open. Zhitao Yang, M.D., from Ruijin Hospital in Shanghai,...